Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 20609968)

1.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF.

Lancet. 2010 Jun 26;375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2.

PMID:
20609968
2.

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators.

Lancet Neurol. 2015 Jun 23. pii: S1474-4422(15)00144-1. doi: 10.1016/S1474-4422(15)00144-1. [Epub ahead of print]

PMID:
26116315
3.

The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.

Lian F, Tian J, Chen X, Li Z, Piao C, Guo J, Ma L, Zhao L, Xia C, Wang CZ, Yuan CS, Tong X.

PLoS One. 2015 Jun 22;10(6):e0130550. doi: 10.1371/journal.pone.0130550. eCollection 2015.

4.

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z.

Lancet. 2015 May 23;385(9982):2057-66. doi: 10.1016/S0140-6736(15)60936-9.

PMID:
26009229
5.

Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.

Sjöström CD, Johansson P, Ptaszynska A, List J, Johnsson E.

Diab Vasc Dis Res. 2015 May 25. pii: 1479164115585298. [Epub ahead of print]

6.

Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial.

Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, Leslie DB, Inabnet WB 3rd, Jeffery RW, Chong K, Chuang LM, Sarr MG, Jensen MD, Vella A, Ahmed L, Belani K, Schone JL, Olofson AE, Bainbridge HA, Laqua PS, Wang Q, Korner J.

Lancet Diabetes Endocrinol. 2015 Jun;3(6):413-22. doi: 10.1016/S2213-8587(15)00089-3. Epub 2015 May 12.

PMID:
25979364
7.

Oral and Injectable (Non-insulin) Pharmacological Agents for Type 2 Diabetes.

Evans JL, Balkan B, Rushakoff RJ.

In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2013 Dec 12.

8.

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.

Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ.

Diabetes Care. 2015 Jul;38(7):1218-27. doi: 10.2337/dc14-0315. Epub 2015 Apr 7.

PMID:
25852208
9.

Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial.

Ross S, Thamer C, Cescutti J, Meinicke T, Woerle HJ, Broedl UC.

Diabetes Obes Metab. 2015 Jul;17(7):699-702. doi: 10.1111/dom.12469. Epub 2015 May 13.

PMID:
25827441
10.

Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels.

Burton JH, Johnson M, Johnson J, Hsia DS, Greenway FL, Heiman ML.

J Diabetes Sci Technol. 2015 Jul;9(4):808-14. doi: 10.1177/1932296815577425. Epub 2015 Mar 23.

PMID:
25802471
12.

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.

Del Prato S, Nauck M, Durán-Garcia S, Maffei L, Rohwedder K, Theuerkauf A, Parikh S.

Diabetes Obes Metab. 2015 Jun;17(6):581-90. doi: 10.1111/dom.12459. Epub 2015 Apr 6.

PMID:
25735400
13.

Does Metformin Treatment Influence Bone Formation in Patients with Nonalcoholic Fatty Liver Disease?

Soifer E, Gavish D, Shargorodsky M.

Horm Metab Res. 2015 Jul;47(8):556-9. doi: 10.1055/s-0034-1395652. Epub 2015 Feb 11.

PMID:
25671801
14.

Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.

de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG.

Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4.

PMID:
25660356
15.

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.

Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M.

Lancet. 2015 Apr 18;385(9977):1511-8. doi: 10.1016/S0140-6736(14)62447-8. Epub 2015 Jan 19.

16.

Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.

Jin SM, Park CY, Cho YM, Ku BJ, Ahn CW, Cha BS, Min KW, Sung YA, Baik SH, Lee KW, Yoon KH, Lee MK, Park SW.

Diabetes Obes Metab. 2015 Jun;17(6):599-602. doi: 10.1111/dom.12435. Epub 2015 Feb 8.

PMID:
25580775
17.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network.

Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7. Erratum in: Lancet. 2015 Mar 14;385(9972):946.

PMID:
25468160
18.

Dapagliflozin does not show improvement in glycemic control in moderate renal impairment: a question of analytical rigor?

Robson AF, Shipman KE.

Kidney Int. 2014 Dec;86(6):1271-2. doi: 10.1038/ki.2014.290. No abstract available.

PMID:
25427091
19.

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF.

Diabet Med. 2015 Apr;32(4):531-41. doi: 10.1111/dme.12624. Epub 2014 Nov 22.

PMID:
25381876
20.

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.

Schumm-Draeger PM, Burgess L, Korányi L, Hruba V, Hamer-Maansson JE, de Bruin TW.

Diabetes Obes Metab. 2015 Jan;17(1):42-51. doi: 10.1111/dom.12387. Epub 2014 Oct 16.

PMID:
25200570
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk